Navigation Links
RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014
Date:7/31/2014

SAN DIEGO, July 31, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its fourth quarter and for the fiscal year ended June 30, 2014.  Revenue for the quarter was $415.2 million, flat compared to the quarter ended June 30, 2013 (a 1 percent decrease on a constant currency basis). Net income was $87.7 million, an increase of 20 percent compared to the quarter ended June 30, 2013. Diluted earnings per share for the quarter were $0.61, an increase of 22 percent compared to the quarter ended June 30, 2013. 

The results for the quarter ended June 30, 2014 were impacted by a $6.3 million ($4.2 million, net of tax) expense for restructuring charges relating to employee termination benefits associated with our reorganization of our commercial and research and development teams.  Non-GAAP net income for the quarter ended June 30, 2014 was $92.0 million, a 1 percent  increase compared to the quarter ended June 30, 2013 (non-GAAP measures exclude the impact of the restructuring expenses in the current quarter and the charge for Sydney University education, research and settlement expenses in the prior year quarter).  Non-GAAP diluted earnings per share for the quarter were $0.64, a 3 percent increase compared to the quarter ended June 30, 2013.  

"Our fourth quarter results were lower than anticipated, the result of softer sales in the Americas, partially offset by good growth in our international markets," said ResMed Chief Executive Officer Mick Farrell.  "We continue to benefit from our globally diversified business, with constant currency revenue growth of 5 percent in our combined Europe and Asia-Pacific businesses."

Highlighting ResMed's new products, Farrell continued, "We see good adoption of our AirFit™ P10 nasal pillows system which is currently the market leader among new patients, and although it is early, we are seeing encouraging traction for our AirFit™ N10 nasal mask and AirFit™ F10 full-face mask which were launched in the fourth quarter around the world. On the flow generator side in the fourth quarter, we launched the Astral™ platform, our new generation of life support ventilators, and are seeing strong uptake in Europe and Asia as sales begin to ramp. During the fourth quarter, we received FDA clearance for the Astral platform in the U.S. and anticipate a U.S. launch by the end of the calendar year." 

Farrell concluded, "We remain focused on capital management, as we continued to repurchase our shares during the quarter.  And today, we announced an increase in our quarterly dividend – the second increase since we began paying a dividend in September 2012.  We are executing against our Three Horizons strategy and expect to return to constant currency top-line growth as we ramp up our new product offerings over fiscal year 2015.  These ResMed solutions are emblematic of our goal to improve patient outcomes and quality of life, while reducing costs for global healthcare systems. In tougher times, we remain committed to disciplined management of our expenses while appropriately funding our long-term opportunities.  We remain excited about the long-term prospects of our business, with ongoing growth opportunities in treating sleep-disordered breathing, chronic obstructive pulmonary disease, and cardiorespiratory diseases."

Analysis of fourth quarter and fiscal year 2014 results
In the fourth quarter of fiscal year 2014, revenue outside the Americas was $200.3 million, a 9 percent increase over the prior year's quarter (5 percent on a constant currency basis). Revenue in the Americas was $214.9 million, a 7 percent decrease compared to $230.3 million in the prior year's quarter.

Gross margin in the fourth quarter was 62.9 percent, 20 basis points higher than the same period in the prior year, due to favorable foreign currency movements, manufacturing improvements, and favorable geographic mix, which were partially offset by declines in average selling prices.

Selling, general and administrative expenses were $122.2 million for the quarter, a 6 percent increase (also a 6 percent increase on a constant currency basis) over the quarter ended June 30, 2013.  SG&A costs were 29.4 percent of revenue in the quarter, compared to 27.8 percent in the quarter ended June 30, 2013, primarily due to higher legal expenses associated with patent litigation.Research and development expenses were $31.8 million for the quarter, or 7.7 percent of revenue.  R&D expenses increased by 1 percent (a 3 percent increase on a constant currency basis) compared to the quarter ended June 30, 2013. 

Operating profit for the fourth quarter was $98.5 million and cash flow from operations was $115.6 million.

ResMed amortized acquired intangibles of $2.4 million ($1.8 million, net of tax) during the quarter.  Stock-based compensation costs incurred during the quarter of $10.8 million ($7.6 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and the company's employee stock purchase plan.  

For the 12 months ended June 30, 2014, revenue was $1,555.0 million, a 3 percent increase over the 12 months ended June 30, 2013 (a 2 percent increase on a constant currency basis).  For the 12 months, net income was $345.3 million, a 12 percent increase compared to the 12 months ended June 30, 2013.  Diluted earnings per share for the 12 months were $2.39 per diluted share, a 14 percent increase compared to the 12 months ended June 30, 2013.

Share repurchase program
During the quarter, the company also repurchased 0.8 million shares at a cost of $40.4 million, as part of its ongoing capital management program.  For the 12 months ended June 30, 2014 the company repurchased 4.4 million shares at a cost of $208.1 million.

Dividend program
The ResMed board of directors has today declared a quarterly dividend of $0.28 per share, which represents a 12 percent increase from the previous quarterly dividend of $0.25.  The dividend will have a record date of Aug. 21, 2014, and be payable on Sept. 18, 2014. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.  The ex-dividend date will be Aug. 19, 2014 for common stock holders and for CDI holders.  ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from Aug. 19, 2014 through Aug. 21, 2014, inclusive.

Webcast details
ResMed will discuss its financial and business results as well as its business outlook on its webcast at 1:30 p.m. U.S. Pacific Daylight Time today. The live webcast of the call can be accessed on ResMed's website at www.resmed.com. Please note that the format of the call has not changed. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player), required to listen to the internet broadcast. The online archive of the broadcast will be available after the live call on ResMed's website. In addition, a telephone replay of the conference call will be available approximately 90 minutes after the call by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering a passcode of 37658760.  The telephone replay will be available from July 31, 2014 until Aug. 14, 2014.

About ResMed
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Safe harbor statement
Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements -- including statements regarding ResMed's projections of future revenue or earnings,  expenses, new product development, new product launches and new markets for its products --  are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission.  ResMed does not undertake to update its forward-looking statements.

Investors:
Agnes Lee
Senior Director, Investor Relations
(858) 836-5971
investorrelations@resmed.com

News Media:
Gretchen Griswold
Director, Global Corporate Communications
(858) 836-6789
news@resmed.com

 RESMED INC. AND SUBSIDIARIESCondensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)Three Months Ended

June 30,

Twelve Months Ended

June 30,2014

2013

2014

2013Net revenue

$415,211

$414,607

$1,554,973

$1,514,457Cost of sales

153,953

154,759

565,187

573,800Gross profit

261,258

259,848

989,786

940,657Operating expenses:Selling, general and administrative

122,242

115,057

450,414

430,802Research and development

31,796

31,390

118,226

120,124Restructuring expenses(1)

6,326

-

6,326

-Education, research and settlement charge (1)

-

24,765

-

24,765Amortization of acquired intangible assets

2,408

2,471

9,733

10,142Total operating expenses

162,772

173,683

584,699

585,833Income from operations (1)

98,486

86,165

405,087

354,824Other income (expenses), net:Interest income (expense), net

5,925

7,439

25,107

32,486Other, net

2,224

(5,777)

884

(2,191)Total other income (expenses), net

8,149

1,662

25,991

30,295Income before income taxes

106,635

87,827

431,078

385,119Income taxes

18,897

14,814

85,805

77,986Net income (1)

$87,738

$73,013

$345,273

$307,133Basic earnings per share

$0.62

$0.51

$2.44

$2.15Diluted earnings per share (1)

$0.61

$0.50

$2.39

$2.10Non-GAAP diluted earnings per share, excluding the impact of restructuring expenses and the education, research and settlement charge (1)

$0.64

$0.62

$2.42

$2.22Basic shares outstanding

140,537

142,669

141,474

142,954Diluted shares outstanding

143,086

146,115

144,359

146,410(1)

See reconciliation of non-GAAP financial measures in table at end of press release. 

 RESMED INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited - In thousands)June 30,

June 30,2014

2013AssetsCurrent assets:Cash and cash equivalents

$905,730

$876,048Accounts receivable, net

359,593

318,349Inventories

165,418

145,847Prepayments, deferred income taxes and other current assets

125,468

108,605Total current assets

1,556,209

1,448,849Property, plant and equipment, net

434,277

411,433Goodwill

289,312

274,829Other intangibles

45,198

49,639Deferred income taxes and other non-current assets

35,966

25,971Total non-current assets

804,753

761,872Total assets

$2,360,962

$2,210,721Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable

$85,405

$60,688Accrued expenses

130,656

137,674Deferred revenue

42,370

44,953Income taxes payable

10,392

30,090Deferred income taxes

717

627Current portion of long-term debt

18

300,017Total current liabilities

269,558

574,049Non-current liabilities:Deferred income taxes

10,716

9,895Deferred revenue

16,352

11,928Income taxes payable

5,318

3,564Non-current portion of long-term debt

300,770

769Total non-current liabilities

333,156

26,156Total liabilities

602,714

600,205Stockholders' Equity:Common stock

566

568Additional paid-in capital

1,117,639

1,025,064Retained earnings

1,780,396

1,576,641Treasury stock

(1,291,910)

(1,083,845)Accumulated other comprehensive income

151,557

92,088Total stockholders' equity

$1,758,248

$1,610,516Total liabilities and stockholders' equity

$2,360,962

$2,210,721 

Reconciliation of Non-GAAP Financial Measures (Unaudited)
(In US$ thousands, except share and per share data)

The measure, "non-GAAP operating income" is reconciled with GAAP income from operations below:Three Months Ended

June 30,

Year Ended

June 30,2014

2013

2014

2013GAAP income from operations

98,486

86,165

405,087

354,824Restructuring expenses (A)

6,326

-

6,326

-Education, research and settlement expenses (B)

-

24,765

-

24,765Non-GAAP operating income (excluding the impact of the restructuring, education, research and settlement expenses)

104,812

110,930

411,413

379,589The measure, "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:Three Months Ended

June 30,

Year Ended

June 30,2014

2013

2014

2013GAAP net income

87,738

73,013

345,273

307,133Restructuring expenses, net of tax (A)

4,2224,222Education, research and settlement expenses, net of tax  (B)

-

17,707

-

17,707Non-GAAP net income (excluding the impact of the restructuring, education, research and settlement expenses)

91,960

90,720

349,495

324,840Diluted shares outstanding

143,086

146,115

144,359

146,410GAAP diluted earnings per share

$0.61

$0.50

$2.39

$2.10Non-GAAP diluted earnings per share (excluding the impact of the restructuring, education, research and settlement expenses)

$0.64

$0.62

$2.42

$2.22 

(A) 

The restructuring expenses relate to discrete employee termination benefits associated with the reorganization of our commercial and research and development teams. Management excludes restructuring activities from its evaluation of ongoing operations and believe investors benefit from excluding these charges to facilitate a more meaningful evaluation of current operating performance.(B) 

The education, research and settlement charge relates to an agreement reached with the University of Sydney, in the fourth quarter of fiscal year 2013, to pay A$25 million (US$24.8 million) for the establishment of two perpetual academic chairs, the funding of future research in the fields of sleep medicine and biomedical engineering and the settlement of legal proceedings between the parties.ResMed believes that presenting diluted earnings per share, excluding the impact of the charge for the restructuring, education, research and settlement expenses is an additional measure of performance that investors can use to compare operating results between reporting periods. Management uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods.  Management believes this information provides investors better insight in evaluating the Company's performance from core operations and provides consistency in financial reporting.  Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a


'/>"/>
SOURCE ResMed Inc.
Copyright©2014 PR Newswire.
All rights reserved


Related medicine technology :

1. ResMed riceve uningiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa
2. ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
3. ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
4. ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results
5. ResMeds New Nasal Pillows System is Our Quietest Yet; Ultra-light AirFit P10 Packs Powerful Performance in Just over 1.5 Ounces
6. ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results
7. BMC to protect its rights in patent fight with ResMed
8. Apex reagiert energisch auf ResMed Patentklage
9. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
10. ResMed Inc. Announces Record Financial Results For The Quarter Ended September 30, 2013
11. ResMeds New Nasal Mask Sets the Bar for Comfort and Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Governor Andrew M. Cuomo today announced ... jobs throughout Western New York . ... SUNY Polytechnic Institute, includes a major expansion of Athenex,s ... Buffalo , as well as the creation ... Dunkirk . The combined projects are ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
(Date:2/11/2016)... -- Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or ... go, ALEX is said to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... The annual list showcases the 20 Most Promising SharePoint Solution Providers in ... commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s editorial ... and promote technology entrepreneurship. , The survey was made at the end of ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical Group ... heart of Old Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be ... of medical care in the convenience of their homes, offices or at the practices’ ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan ... force gauges used in physical therapy, occupational therapy and sports medicine clinics, hospitals, ... cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. , ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... become more actively engaged in health and wellness best practices in the past ... riding this trend. February is American Heart Month, which acts as an exceptional ...
Breaking Medicine News(10 mins):